Literature DB >> 31577391

An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data.

Francis Lacombe1, Nicolas Lechevalier1, Jean Philippe Vial1, Marie C Béné2.   

Abstract

Multiparameter flow cytometry (MFC) is a powerful and versatile tool to accurately analyze cell subsets, notably to explore normal and pathological hematopoiesis. Yet, mostly supervised subjective strategies are used to identify cell subsets in this complex tissue. In the past few years, the implementation of mass cytometry and the big data generated have led to a blossoming of new software solutions. Their application to classical MFC in hematology is however still seldom reported. Here, we show how one of these new tools, the FlowSOM R solution, can be applied, together with the Kaluza® software, to a new delineation of hematopoietic subsets in normal human bone marrow (BM). We thus combined the unsupervised discrimination of cell subsets provided by FlowSOM and their expert-driven node-by-node assignment to known or new hematopoietic subsets. We also show how this new tool could modify the MFC exploration of hematological malignancies both at diagnosis (Dg) and follow-up (FU). This can be achieved by direct comparison of merged listmodes of reference normal BM, Dg, and FU samples of a representative acute myeloblastic case tested with the same immunophenotyping panel. This provides an immediate unsupervised evaluation of minimal residual disease.
© 2019 International Society for Advancement of Cytometry. © 2019 International Society for Advancement of Cytometry.

Entities:  

Keywords:  FlowSOM; MRD; bone marrow; flow cytometry; machine learning

Year:  2019        PMID: 31577391     DOI: 10.1002/cyto.a.23897

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  10 in total

Review 1.  Analyzing high-dimensional cytometry data using FlowSOM.

Authors:  Katrien Quintelier; Artuur Couckuyt; Annelies Emmaneel; Joachim Aerts; Yvan Saeys; Sofie Van Gassen
Journal:  Nat Protoc       Date:  2021-06-25       Impact factor: 13.491

2.  Diagnosis of Acute Leukemia by Multiparameter Flow Cytometry with the Assistance of Artificial Intelligence.

Authors:  Pengqiang Zhong; Mengzhi Hong; Huanyu He; Jiang Zhang; Yaoming Chen; Zhigang Wang; Peisong Chen; Juan Ouyang
Journal:  Diagnostics (Basel)       Date:  2022-03-28

3.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

4.  Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia.

Authors:  Jean Philippe Vial; Nicolas Lechevalier; Francis Lacombe; Pierre-Yves Dumas; Audrey Bidet; Thibaut Leguay; François Vergez; Arnaud Pigneux; Marie C Béné
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

5.  Implementing flowDensity for Automated Analysis of Bone Marrow Lymphocyte Population.

Authors:  Ghazaleh Eskandari; Sishir Subedi; Paul Christensen; Randall J Olsen; Youli Zu; Scott W Long
Journal:  J Pathol Inform       Date:  2021-12-09

6.  Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.

Authors:  Jesse M Tettero; Sylvie Freeman; Veit Buecklein; Adriano Venditti; Luca Maurillo; Wolfgang Kern; Roland B Walter; Brent L Wood; Christophe Roumier; Jan Philippé; Barbara Denys; Jeffrey L Jorgensen; Marie C Bene; Francis Lacombe; Adriana Plesa; Monica L Guzman; Agnieszka Wierzbowska; Anna Czyz; Lok Lam Ngai; Adrian Schwarzer; Costa Bachas; Jacqueline Cloos; Marion Subklewe; Michaela Fuering-Buske; Francesco Buccisano
Journal:  Hemasphere       Date:  2021-12-22

7.  Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.

Authors:  Uta Oelschlägel; Malte von Bonin; Maximilian A Röhnert; Michael Kramer; Jonas Schadt; Philipp Ensel; Christian Thiede; Stefan W Krause; Veit Bücklein; Jörg Hoffmann; Sonia Jaramillo; Richard F Schlenk; Christoph Röllig; Martin Bornhäuser; Nicholas McCarthy; Sylvie Freeman
Journal:  Leukemia       Date:  2022-07-18       Impact factor: 12.883

8.  Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic Flow-Self Organizing Maps algorithm.

Authors:  Anna Porwit; Despoina Violidaki; Olof Axler; Francis Lacombe; Mats Ehinger; Marie C Béné
Journal:  Cytometry B Clin Cytom       Date:  2022-02-12       Impact factor: 3.248

9.  AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

Authors:  Diana Hanekamp; Jesse M Tettero; Gert J Ossenkoppele; Angèle Kelder; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Flow Cytometric Analyses of Lymphocyte Markers in Immune Oncology: A Comprehensive Guidance for Validation Practice According to Laws and Standards.

Authors:  Claude Lambert; Gulderen Yanikkaya Demirel; Thomas Keller; Frank Preijers; Katherina Psarra; Matthias Schiemann; Mustafa Özçürümez; Ulrich Sack
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.